A concise survey of L. Dérer's work on biorhythmicity.

Ruttkay-Nedecký I.

Biography 2003; 24(6): 11-12 PubMed PMID: 15077066 Keywords: History, 19th Century, History, 20th Century, Humans, Neuroendocrinology:history, Periodicity, Slovakia,.

Full text PDF

Relation between functional polymorphism of catalase gene (-262C>T) and recurrent depressive disorder.

Galecki P, Szemraj J, Zboralski K, Florkowski A, Lewinski A.

Biography

2009; 30(3): 357-362

PubMed PMID: 19855359

Citation

Citation

Galecki P, Szemraj J, Zboralski K, Florkowski A, Lewinski A. Relation between functional polymorphism of catalase gene (-262C>T) and recurrent depressive disorder. Neuro Endocrinol Lett. 2009 Jan; 30(3): 357-362

Distinct lethal arrhythmias susceptibility is associated with sex-related difference in myocardial connexin-43 expression.

Knezl V, Bacova B, Kolenova L, Mitasikova M, Weismann P, Drimal J, Tribulova N.

Biography

2008; 29(5): 798-801

PubMed PMID: 18987606

Citation

Citation

Knezl V, Bacova B, Kolenova L, Mitasikova M, Weismann P, Drimal J, Tribulova N. Distinct lethal arrhythmias susceptibility is associated with sex-related difference in myocardial connexin-43 expression. Neuro Endocrinol Lett. 2008 Oct; 29(5): 798-801

Somatostatin-receptor positive brain stem glioma visualized by octreoscan.

Pichler R, Pichler J, Mustafa H, Nussbaumer K, Zaunmüller T, Topakian R.

Biography

2007; 28(3): 250-251

PubMed PMID: 17627256

Citation

Citation

Pichler R, Pichler J, Mustafa H, Nussbaumer K, Zaunmüller T, Topakian R. Somatostatin-receptor positive brain stem glioma visualized by octreoscan. Neuro Endocrinol Lett. 2007 Jun; 28(3): 250-251

Salivary alpha-amylase levels and hyperbolic discounting in male humans.

Takahashi T, Ikeda K, Fukushima H, Hasegawa T.

Biography

2007; 28(1): 17-20

PubMed PMID: 17277731

Citation

Citation

Takahashi T, Ikeda K, Fukushima H, Hasegawa T. Salivary alpha-amylase levels and hyperbolic discounting in male humans. Neuro Endocrinol Lett. 2007 Feb; 28(1): 17-20

A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.

Lissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G.

Biography

2002; 23(3): 255-258

PubMed PMID: 12080288

Citation

Citation

Lissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Neuro Endocrinol Lett. 2002 Jun; 23(3): 255-258